Protein nano-fibrilar structure and associated diseases

Current Proteomics

Volumn 7, Issue 2, 2010, Pages 116-120

  Sarkar, Nandini ^a   Dubey, Vikash Kumar ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

Diseases; Nano fibrils; Protein folding

Indexed keywords

EID: 77954700788     PISSN: 15701646     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016410791330516     Document Type: Article

References (42)

1. Dubey, V.K.; Lee, J. and Blaber, M. Redesigning symmetry-related "mini-core" regions of FGF-1 to increase primary structure symmetry: Thermodynamic and functional consequences of structural symmetry. Prot. Sci., 2005, 14, 2315-2323.
2. Nallamsetty, S.; Dubey, V.K.; Pande, M.; Ambasht, P.K. and Jagannadham, M.V. Accumulation of partly folded states in the equilibrium unfolding of ervatamin A: spectroscopic description of the native, intermediate, and unfolded states. Biochimie, 2007, 89, 1416-1424.
3. Shirahama, T. and Cohen, A.S. High-resolution electron microscopic analysis of the amyloid fibril. J. Cell Biol., 1963, 33, 679-708.
4. Anfinsen, C.B. Principles that govern the folding of protein chains. Science, 1973, 181, 223-230.
5. Hardesty, B. and Kramer, G. Folding of a nascent peptide on the ribosome. Prog. Nucleic Acid Res. Mol. Biol., 2001, 66, 41-66.
6. Barral, J.M.; Broadley, S.A.; Schaffar, G. and Hartl, F.U. Roles of molecular chaperones in protein misfolding diseases. Semin. Cell Dev. Biol., 2004, 15, 17-29.
7. Liberek, K.; Lewandowska, A. and Zietkiewicz, S. Chaperones in control of protein disaggregation. EMBO J., 2008, 27, 328-335.
8. Kaganovich, D.; Kopito, R. and Frydman, J. Misfolded proteins partition between two distinct quality control compartments. Nature, 2008, 454, 1088-1095.
9. Howard, M. and Welch, W.J. Manipulating the folding pathway of F508 CFTR using chemical chaperones. Methods Mol. Med., 2002, 70, 267-275.
10. Carrell, R.W. and Lomas, D.A. Mechanisms of disease. Alpha1antitrypsin deficiency-a model for conformational diseases. N. Engl. J. Med., 2002, 346, 45-53.
11. Chiti, F. and Dobson, C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem., 2006, 75, 333-366.
12. Leandro, P. and Gomes, C.M. Proteins misfolding in conformational disorders: rescue of folding defects and chemical chaperoning. Mini Rev. Med. Chem., 2008, 8, 901-911.
13. Stefani, M. Protein misfolding and aggregation: new examples in medicine and biology of dark side of protein world. Biochem et Biophys. Acta, 2004, 81, 678-699.
14. Heise, H.; Celej, M.S.; Becker, S.; Riedel, D.; Pelah, A.; Kumar, A.; Jovin, T.M. and Baldus, M. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant-synuclein. J. Mol. Biol., 2008, 380, 444-450.
15. Dobson, C.M. Protein folding and misfolding. Nature, 2003, 426, 884-890.
16. Sunde, M. and Blake, C.C.F. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv. Protein Chem., 1997, 50, 123-159.
17. Dobson, C.M. Protein misfolding, evolution and disease. Trends Biochem. Sci., 1999, 24, 329-332.
18. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W. and Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300, 486-489.
19. Sarkar, N.; Singh, A.N. and Dubey, V.K. Effect of curcumin on amyloidogenic property of molten globule like intermediate state of 2,5-Diketo-D-Gluconate reductase A. Biol Chem., 2009, 390, 1057-1061.
20. Stefani, M. and Dobson, C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med., 2003, 81, 678-699.
21. Bucciantini, M.; Giannoni, E.; Chiti, F.; Baroni, F.; Formigli, L.; Zurdo, J.; Taddei, N.; Ramponi, G.; Dobson, C.M.; Stefani, M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature, 2002, 416, 507-511.
22. Horwich, A. Protein aggregation in disease: a role of folding intermediates forming specific multimeric interactions. J. Clin. Invest., 2002, 110, 1221-1232.
23. Pai, A.S.; Rubinstein, I. and Onyuksel, H. PEGylated phospholipid nanomicelles interact with beta-amyloid((1-42)) and mitigate its beta-sheet formation, aggregation and neurotoxicity in vitro. Peptides, 2006, 27, 2858-2866.
24. Shea, T.B.; Robert, D.O.; Nicolosi, R.J.; Kumar, R. and Watterson, A.C. Nanosphere-mediated delivery of vitamin E increases its efficacy against oxidative stress resulting from exposure to amyloid beta. J. Alzheimers Dis., 2005, 7, 297-301.
25. Ikeda, K.; Okada, T., Sawada, S-I.; Akiyoshi, K. and Matsuzaki, K. Inhibition of the formation of amyloid beta-protein fibrils using biocompatible nanogels as artificial chaperones. FEBS Lett., 2006, 580, 6587-6595.
26. Liu, G.; Men, P.; Harris, P.L.; Rolston, R.K.; Perry, G. and Smith, M.A. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett., 2006, 406, 189-193.
27. Georganopoulou, D.G.; Chang, L.; Nam, J-M.; Thaxton, C.S.; Mufson, E.J.; Klein, W.L. and Mirkin, C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2005, 102, 2273-2276.
28. Fischer, H.; Fukuda, N.; Barbry, P.; Illek, B.; Sartori, C. and Matthay, M.A. Partial restoration of defective chloride conductance in DeltaF508 CF mice by trimethylamine oxide. Am. J. Physiol.: Lung Cell. Mol. Physiol., 2001, 281, L52-L57.
29. Sawkar, A.R.; Cheng, W.C.; Beutler, E.; Wong, C.H.; Balch, W.E. and Kelly, J.W. Chemical chaperones increase the cellular activity of N370S -glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl Acad. Sci. USA, 2002, 99, 15428-15433.
30. Elstein, D.; Dweck, A.; Attias, D.; Hadas-Halpern, I.; Zevin, S.; Altarescu, G.; Aerts. J.F.; van Weely, S. and Zimran A. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood, 2007, 110, 2296-2301.
31. Hollstein, M.; Sidransky, D.; Vogelstein, B. and Harris, C.C. p53 mutations in human cancers. Science, 1991, 253, 49-53.
32. Friedler, A.; Hansson, L.O.; Veprintsev, D.B.; Freund, S.M.V.; Rippin, T.M.; Nikolova, P.V.; Proctor, M.R.; Rüdiger, S. and Fersht, A.R. A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. USA, 2002, 99, 2937-2942.
33. Higashimoto, Y.; Asanomi, Y.; Takakusagi, S.; Lewis, M.S.; Uosaki, K.; Durell, S.R.; Anderson, C.W.; Appella, E. and Sakaguchi K. Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry, 2006, 45, 1608-1619.
34. Priller, C.; Bauer, T.; Mitteregger, G.; Krebs, B.; Kretzschmar, H.A. and Herms, J. Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci., 2006, 26, 7212-7221.
35. Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; Chen, P.P.; Kayed, R.; Glabe, C.G.; Frautschy, S.A. and Cole, G.M. Curcumin Inhibits Formation of amyloid oligomers and fibrils, binds plaques and reduces amyloid in vivo. J. Biol. Chem., 2005, 280, 5892-5901.
36. Doig, A.J. Peptide inhibitors of -amyloid aggregation. Curr. Opin. Drug Discov. Develop., 2007, 10, 533-539.
37. Takahashi, T.T. and Mihara HH. Peptide and Protein Mimetics Inhibiting Amyloid -Peptide Aggregation. Acc. Chem. Res., 2008, 41, 1309-1318.
38. Torok, B.; Dasgupta, S. and Torok, M. Chemistry of small molecule inhibitors in self-assembly of Alzheimer's disease related amyloid-beta peptide. Curr. Bioactive Compounds, 2008, 4, 159-174.
39. Santa-Maria, I.; Hernández, F.; Del Rio, J.; Moreno, F.J.; Avila, J. Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol. Neurodegener., 2007, 2, 17.
40. Gruschus, J.M.Do. Amyloid oligomers act as traps for misfolded proteins? a hypothesis. Amyloid, 2008, 15,160-165.
41. Fandrich, M.; Fletcher, M.A. and Dobson, C.M. Amyloid fibrils from muscle myoglobin. Nature, 2001, 410, 165-166.
42. Trovato, A.; Chiti, F.; Maritan, A. and Seno, F. Insight into the structure of amyloid fibrils from the analysis of globular proteins. PLoS Comput. Biol., 2006, 2, e170.